Full-Time

Medical Science Liaison

Neurodegeneration

Prilenia

Prilenia

51-200 employees

Develops pridopidine treatments for neurodegenerative diseases

No salary listed

Boston, MA, USA

Remote

Fully remote US role; up to 70% travel (domestic); flexible schedule across NA time zones.

PharmD, PhD, MD

Category
Biology & Biotech (1)
Required Skills
Market Research

Get referred to Prilenia

See people who can refer or advise you

Requirements
  • Advanced degree in life sciences (MD, PhD, PharmD, or equivalent)
  • Minimum of 5 years of reference supported high-performance in a similar Medical Science Liaison role
  • Demonstrated experience working with Key Opinion Leaders and understanding of the United States and Canadian healthcare systems
  • Strong scientific acumen and ability to understand and effectively communicate complex scientific and clinical data
  • Excellent interpersonal and communication skills, both written and verbal
  • Ability to work independently and manage multiple priorities in a fast-paced environment
  • Proficient in Microsoft Office Suite and familiar with Customer Relationship Management tools
  • This is a full-time remote position in the United States
  • Expected domestic/regional travel up to 70% with some international travel
  • Valid driver's license required
Responsibilities
  • Identify, develop, and maintain relationships with Key Opinion Leaders (KOLs), healthcare professionals (HCPs), and other stakeholders within the relevant therapeutic areas
  • Engage in scientific exchange to provide and gather medical and scientific insights
  • Represent the company at medical conferences, symposia, and meetings to establish and strengthen relationships with KOLs and other stakeholders
  • Provide accurate, unbiased, and up-to-date scientific information to healthcare professionals
  • Present clinical data and scientific information in advisory boards, investigator meetings, and educational sessions
  • Serve as a scientific resource for internal and external stakeholders
  • Collaborate with cross-functional teams, including Clinical, Research, Regulatory, Patient Advocacy and Commercial, to provide scientific input and support
  • Assist in the development of medical strategy and contribute to the execution of Medical Affairs plans
  • Support Clinical Development initiatives, including site identification and patient recruitment for clinical trials
  • Gather and communicate competitive intelligence and market insights to inform strategic decisions
  • Provide feedback to internal teams on trends and emerging science in the field
  • Leverage scientific knowledge and KOL relationships to identify opportunities for activities leading to scientific advancement
  • Ensure all activities and interactions comply with applicable local and international regulations, company policies, and ethical standards
Desired Qualifications
  • Experience in neurology and neurodegenerative therapeutic areas relevant to the company’s pipeline is highly desired

Prilenia develops and commercializes medicines for brain diseases. It focuses on creating treatments for neurodegenerative conditions (like Huntington’s disease and ALS) and neurodevelopmental disorders. Its main candidate is pridopidine, a drug studied to help brain cells by activating the sigma-1 receptor (S1R), which researchers believe can help restore brain pathways impaired in these diseases. The product works by engaging S1R to support neuronal function, with the goal of slowing symptoms or progression once approved. Prilenia aims to stand out by its specific focus on S1R biology, building a pipeline of potential therapies, and bringing these treatments to patients through regulatory approval and commercialization. The company’s goal is to provide validated therapies that address urgent needs for patients and families affected by neurodegenerative and neurodevelopmental disorders, while growing its team and expanding its pipeline for future medicines.

Company Size

51-200

Company Stage

Series B

Total Funding

$115.5M

Headquarters

Herzliya, Israel

Founded

2018

Get referred to Prilenia

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • PRECISE-HD started July 7, 2026, and PREVAiLS enrolled first patients March 30, 2026.
  • Prilenia's May 26, 2026 CHDI data-sharing deal strengthens HD credibility and external validation.
  • The April 28, 2026 CFO hire shows financing discipline heading into expensive Phase 3 execution.

What critics are saying

  • EMA withdrew Nurzigma in November 2025, proving Europe rejected pridopidine without more data.
  • Prilenia remains a single-asset company; PRECISE-HD and PREVAiLS failure kills the platform.
  • ALS and HD enrollments in 2026 create a multi-year cash burn before any approval.

What makes Prilenia unique

  • Prilenia’s pridopidine targets sigma-1 receptor biology across Huntington’s disease and ALS.
  • Ferrer’s April 2025 license gives Prilenia ex-U.S. commercialization reach and non-dilutive milestones.
  • PRECISE-HD and PREVAiLS make Prilenia one of few companies running two Phase 3 brain-disease trials.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Wellness Program

Mental Health Support

Conference Attendance Budget

Family Planning Benefits

Fertility Treatment Support

Stock Options

401(k) Retirement Plan

401(k) Company Match

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

8%
Associated Press
Apr 28th, 2026
Prilenia names Dr. Elisabeth Leiderman as CFO to lead financial strategy through Phase 3 trials

Prilenia Therapeutics, a biopharmaceutical company focused on Huntington's disease and Amyotrophic Lateral Sclerosis treatments, has appointed Dr Elisabeth Leiderman as Chief Financial Officer. Leiderman brings over 20 years of finance and corporate development experience in life sciences. She has previously served as CFO at multiple biotech companies including Dewpoint, Atsena and Decibel, and currently sits on the board of Autolus Therapeutics. She also held senior investment banking positions at UBS, Credit Suisse and Nomura. The appointment comes as Prilenia embarks on two Phase 3 studies for its drug pridopidine in HD and ALS. Leiderman will focus on managing the company's financial runway through Phase 3 completion whilst preparing for potential commercialisation.

AIJourn
Apr 28th, 2025
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets

NAARDEN, Netherlands & WALTHAM, Mass. - (BUSINESS WIRE) - Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets.

BioSpace
Sep 19th, 2024
Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer

Prilenia appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal Officer.

Business Wire
Apr 12th, 2024
Prilenia To Present Latest Research From Its Pridopidine Programs For Huntington Disease And Als At Aan 2024

NAARDEN, Netherlands WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced the presentation of the latest research from the pridopidine Huntington disease (HD) and amyotrophic lateral sclerosis (ALS) programs at the American Academy of Neurology (AAN) Annual Congress, in Denver, Colorado, April 13-18. “Pridopidine is now in pre-registration phase in HD, with a first submission planned Mid 2024i, and is also set to commence a global Phase 3 study in ALS later this year. We are making significant strides forward and this is reflected by presentation of the data at one of the most important medical congresses in the field of Neurology,” said Jina Swarz, MD. Ph.D., the recently appointed Chief Medical Officer of Prilenia. “Pridopidine is one of the most advanced investigational new drugs in HD and ALS and has shown consistent treatment benefits across independent measures that are important to patients and families. The presented data advances knowledge in the field, providing important learnings for both clinical practice and for the design of our programs going forward

Business Wire
Mar 12th, 2024
Prilenia Plans To Submit Marketing Authorization Application (Maa) In The Eu For Pridopidine In Huntington’S Disease

NAARDEN, Netherlands WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, announced its plan to submit a Marketing Authorization Application (MAA) for pridopidine for the treatment of Huntington’s disease (HD) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). This decision follows positive pre-submission meetings with regulatory authorities in the European Union. Submission is planned for mid-2024. “Pridopidine demonstrates consistent treatment benefits across independent measures that are important to patients and families. These measures include day-to-day function, cognition, motor and clinical progression in people living with HD. The benefits are clearly evident in those with HD who are not taking anti-dopaminergic medications (ADM),” said Dr